corcept8k.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
Current Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of
earliest event reported): August 12,
2010
Corcept
Therapeutics Incorporated
(Exact
name of registrant as specified in its charter)
000-50679
(Commission File
Number)
| |
Delaware |
77-0487658 |
|
| |
(State or
other jurisdiction of |
(I.R.S.
Employer Identification No.) |
|
| |
incorporation) |
|
|
149
Commonwealth Drive
Menlo
Park, CA 94025
(Address
of principal executive offices, with zip code)
(650)
327-3270
(Registrant's
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
|
o
|
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
2.02 Results of Operations and Financial Condition
On August
12, 2010, Corcept Therapeutics Incorporated (the “Company”), issued a press
release announcing its financial results for the quarter ended June 30,
2010. The press release is attached hereto as Exhibit 99.1 and
incorporated by reference herein.
The
information in this Item 2.02 and the information contained in the press release
attached as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18
of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities
of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as
amended. The information in this Item 2.02 and the information contained in the
press release attached as Exhibit 99.1 shall not be incorporated by reference
into any filing with the U.S. Securities and Exchange Commission made by the
Company, whether made before or after the date hereof, regardless of any general
incorporation language in the filing unless specifically stated so
therein.
Item
7.01 Regulation FD Disclosure
On August
12, 2010, the Company issued a press release announcing its financial results
for the quarter ended June 30, 2010. The press release is attached
hereto as Exhibit 99.1 and incorporated by reference herein.
The
information in this Item 7.01 and the information contained in the press release
attached as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18
of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities
of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as
amended. The information in this Item 7.01 and the information contained in the
press release attached as Exhibit 99.1 is not incorporated by reference into any
filing with the U.S. Securities and Exchange Commission made by the Company,
whether made before or after the date hereof, regardless of any general
incorporation language in the filing unless specifically stated so
therein.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
The
following exhibit is furnished with this Current Report on Form
8-K:
99.1
Press Release of Corcept Therapeutics Incorporated
dated August 12, 2010.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
| |
CORCEPT THERAPEUTICS
INCORPORATED |
| Date: August
16, 2010 |
By: /s/ Caroline M.
Loewy
|
| |
Caroline
M. Loewy |
| |
Chief Financial Officer |